Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 1.430
Filtrar
2.
Clin Lab Med ; 40(4): 587-601, 2020 12.
Artículo en Inglés | MEDLINE | ID: mdl-33121624

RESUMEN

SARS-CoV-2 (also known as COVID-19) has been an unprecedented challenge in many parts of the medical field with blood banking being no exception. COVID-19 has had a distinctly negative effect on our blood collection nationwide forcing blood banks, blood centers, and the US government to adopt new policies to adapt to a decreased blood supply as well as to protect our donors from COVID-19. These policies can be seen distinctly in patient blood management and blood bank operations. We are also faced with developing policies and procedures for a nontraditional therapy, convalescent plasma; its efficacy and safety is still not completely elucidated as of yet.


Asunto(s)
Bancos de Sangre , Transfusión Sanguínea/normas , Infecciones por Coronavirus , Control de Infecciones/organización & administración , Pandemias , Neumonía Viral , Betacoronavirus , Bancos de Sangre/métodos , Bancos de Sangre/tendencias , Donantes de Sangre/provisión & distribución , Seguridad de la Sangre , Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/prevención & control , Humanos , Pandemias/prevención & control , Neumonía Viral/epidemiología , Neumonía Viral/prevención & control , Formulación de Políticas , Medicina Transfusional/normas , Medicina Transfusional/tendencias
3.
BMC Infect Dis ; 20(1): 736, 2020 Oct 07.
Artículo en Inglés | MEDLINE | ID: mdl-33028232

RESUMEN

BACKGROUND: Blood transfusion is associated with potential risks of transfusion-transmitted infections (TTIs). Different strategies are needed to monitor blood safety and screen the donors' efficacy, such as evaluation of the prevalence and trends of TTIs. This study was conducted to evaluate the prevalence and trends of TTIs, including hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), and human T-cell lymphotropic virus (HTLV 1/2), and the impact of the donors' characteristics such as age, sex, and donor status on the prevalence of TTIs in blood donors in seven large provinces of Iran from 2010 to 2018. METHODS: This study was conducted on the data collected from all blood donations in seven Iranian Blood Transfusion Centers including Ardabil, Alborz, Guilan, West Azarbaijan, North, Razavi, and South Khorasan from April 2010 to March 2018. Demographic characteristics, number of donations, donor status, and screening and confirmatory serological results of all blood donations were collected from Iranian Blood Transfusion Organizations (IBTO) national database. The prevalence and trend of HBV, HCV, HIV, and HTLV 1/2 infections were reported according to the donation year and donor's characteristics. RESULTS: The analysis of the prevalence and trend of TTIs in 3,622,860 blood donors showed a significant decreasing trend in first-time and regular donors. Additionally, compared to first- time donors, regular donors made safer blood donations with lower risks of HBV, HIV, HCV and HTLV 1/2 (P < 0.0001). Although the prevalence of HTLV 1/2 and HBV was higher in females, TTIs had a significant decreasing trend in males and females. Finally, it was found that the prevalence of HBV and HTLV 1/2 increased with age up to 40-49 years and then decreased thereafter. CONCLUSIONS: The decreasing trends of TTIs in Iranian donors during 9 years may indicate that the various strategies implemented by IBTO have been effective in recent years. Other factors such as a decrease in the prevalence of specific TTIs in the general population might have also contributed to these declines.


Asunto(s)
Seguridad de la Sangre , Infecciones por VIH/diagnóstico , Infecciones por HTLV-I/diagnóstico , Hepatitis B/diagnóstico , Hepatitis C/diagnóstico , Adolescente , Adulto , Donantes de Sangre/estadística & datos numéricos , Femenino , Infecciones por VIH/epidemiología , Infecciones por HTLV-I/epidemiología , Hepatitis B/epidemiología , Hepatitis C/epidemiología , Humanos , Irán/epidemiología , Masculino , Persona de Mediana Edad , Prevalencia , Reacción a la Transfusión/diagnóstico , Reacción a la Transfusión/epidemiología , Reacción a la Transfusión/virología , Adulto Joven
4.
J Med Life ; 13(2): 211-218, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32742516

RESUMEN

The present study aimed to propose a model for the national hemovigilance information system with a database approach, considering the importance and necessity of developing an information system for such a network. This is an applied, descriptive, and cross-sectional study, which was conducted in 2018. The research population comprised hemovigilance information systems in advanced countries, including the USA, UK, Australia, and France. Data were collected from library sources and the Internet from 2000 to 2018. The proposed model for the national hemovigilance information system was introduced using comparative tables and based on the similarities and differences of systems in the studied countries. The proposed model was then validated using the two-step Delphi technique through a researcher-made questionnaire whose validity was confirmed, and reliability was approved by a Cronbach's alpha of 94%. The final model of the national hemovigilance information system comprised five main components: goals, organizations involved in the blood transfusion process, databases of blood transfusion organizations, data transfer flow between the databases of blood transfusion organizations, and transferable datasets, and hemovigilance-related committees. This model was approved by experts with an >85% agreement coefficient. The national hemovigilance information system with a database approach can improve blood transfusion health by providing access to reliable sources on blood transfusion complications to everyone, especially the medical community. Thus, it is essential to implement this standard accurately and precisely control the practical methods of this process based on international guidelines.


Asunto(s)
Seguridad de la Sangre , Sistemas de Información , Modelos Teóricos , Transfusión Sanguínea , Estudios Transversales , Humanos , Irán , Reproducibilidad de los Resultados , Reacción a la Transfusión/epidemiología , Reacción a la Transfusión/etiología
5.
PLoS Negl Trop Dis ; 14(7): e0008438, 2020 07.
Artículo en Inglés | MEDLINE | ID: mdl-32663213

RESUMEN

BACKGROUND: Since 2015, Zika virus (ZIKV) outbreaks have occurred in the Americas and the Pacific involving mosquito-borne and sexual transmission. ZIKV has also emerged as a risk to global blood transfusion safety. Aedes aegypti, a mosquito well established in north and some parts of central and southern Queensland, Australia, transmits ZIKV. Aedes albopictus, another potential ZIKV vector, is a threat to mainland Australia. Since these conditions create the potential for local transmission in Australia and a possible uncertainty in the effectiveness of blood donor risk-mitigation programs, we investigated the possible impact of mosquito-borne and sexual transmission of ZIKV in Australia on local blood transfusion safety. METHODOLOGY/PRINCIPAL FINDINGS: We estimated 'best-' and 'worst-' case scenarios of monthly reproduction number (R0) for both transmission pathways of ZIKV from 1996-2015 in 11 urban or regional population centres, by varying epidemiological and entomological estimates. We then estimated the attack rate and subsequent number of infectious people to quantify the ZIKV transfusion-transmission risk using the European Up-Front Risk Assessment Tool. For all scenarios and with both vector species R0 was lower than one for ZIKV transmission. However, a higher risk of a sustained outbreak was estimated for Cairns, Rockhampton, Thursday Island, and theoretically in Darwin during the warmest months of the year. The yearly estimation of the risk of transmitting ZIKV infection by blood transfusion remained low through the study period for all locations, with the highest potential risk estimated in Darwin. CONCLUSIONS/SIGNIFICANCE: Given the increasing demand for plasma products in Australia, the current strategy of restricting donors returning from infectious disease outbreak regions to source plasma collection provides a simple and effective risk management approach. However, if local transmission was suspected in the main urban centres of Australia, potentially facilitated by the geographic range expansion of Ae. aegypti or Ae. albopictus, this mitigation strategy would need urgent review.


Asunto(s)
Aedes/virología , Donantes de Sangre , Seguridad de la Sangre/normas , Mosquitos Vectores/virología , Enfermedades Virales de Transmisión Sexual/transmisión , Infección por el Virus Zika/transmisión , Animales , Australia/epidemiología , Enfermedades Transmisibles Emergentes/epidemiología , Brotes de Enfermedades , Humanos , Modelos Biológicos , Salud Pública , Reproducibilidad de los Resultados , Enfermedades Virales de Transmisión Sexual/sangre , Enfermedades Virales de Transmisión Sexual/epidemiología , Virus Zika/fisiología , Infección por el Virus Zika/epidemiología , Infección por el Virus Zika/virología
6.
Lancet Haematol ; 7(10): e756-e764, 2020 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-32628911

RESUMEN

The COVID-19 pandemic has major implications for blood transfusion. There are uncertain patterns of demand, and transfusion institutions need to plan for reductions in donations and loss of crucial staff because of sickness and public health restrictions. We systematically searched for relevant studies addressing the transfusion chain-from donor, through collection and processing, to patients-to provide a synthesis of the published literature and guidance during times of potential or actual shortage. A reduction in donor numbers has largely been matched by reductions in demand for transfusion. Contingency planning includes prioritisation policies for patients in the event of predicted shortage. A range of strategies maintain ongoing equitable access to blood for transfusion during the pandemic, in addition to providing new therapies such as convalescent plasma. Sharing experience and developing expert consensus on the basis of evolving publications will help transfusion services and hospitals in countries at different stages in the pandemic.


Asunto(s)
Betacoronavirus , Bancos de Sangre/estadística & datos numéricos , Donantes de Sangre/provisión & distribución , Transfusión Sanguínea , Infecciones por Coronavirus , Pandemias , Neumonía Viral , Anticuerpos Antivirales/uso terapéutico , Trastornos de la Coagulación Sanguínea/etiología , Trastornos de la Coagulación Sanguínea/terapia , Conservación de la Sangre , Seguridad de la Sangre , Transfusión Sanguínea/estadística & datos numéricos , Infecciones por Coronavirus/sangre , Infecciones por Coronavirus/complicaciones , Infecciones por Coronavirus/prevención & control , Infecciones por Coronavirus/terapia , Selección de Donante , Procedimientos Quirúrgicos Electivos , Asignación de Recursos para la Atención de Salud , Política de Salud , Necesidades y Demandas de Servicios de Salud , Hemoglobinopatías/complicaciones , Hemoglobinopatías/terapia , Humanos , Inmunización Pasiva , Pandemias/prevención & control , Neumonía Viral/sangre , Neumonía Viral/complicaciones , Neumonía Viral/prevención & control , Neumonía Viral/terapia , Ensayos Clínicos Controlados Aleatorios como Asunto
9.
Epidemiol Infect ; 148: e158, 2020 06 29.
Artículo en Inglés | MEDLINE | ID: mdl-32594963

RESUMEN

While the majority of worldwide hepatitis E viral (HEV) infections that occur in people are from contaminated water or food sources, there has also been a steadily rising number of reported cases of transfusion-transmitted HEV (TT-HEV) in blood donation recipients. For most, HEV infection is acute, self-limiting and asymptomatic. However, patients that are immunocompromised, especially transplant patients, are at much higher risk for developing chronic infections, which can progress to cirrhosis and liver failure, along with overall increased mortality. Because of the rising trend of HEV serological prevalence among the global population, and the fact that TT-HEV infection can cause serious clinical consequences among those patients most at need for blood donation, the need for screening for TT-HEV has been gaining in prominence as an important public health concern for both developing and developed countries. In the review, we summarise evidence for and notable cases of TT-HEV infections, the various aspects of HEV screening protocols and recent trends in the implementation of TT-HEV broad-based blood screening programmes.


Asunto(s)
Seguridad de la Sangre , Transfusión Sanguínea , Virus de la Hepatitis E , Hepatitis E/sangre , Hepatitis E/transmisión , Donantes de Sangre , Humanos
10.
Afr J Prim Health Care Fam Med ; 12(1): e1-e3, 2020 May 21.
Artículo en Inglés | MEDLINE | ID: mdl-32501018

RESUMEN

The coronavirus disease 2019 (COVID-19) pandemic has highlighted various weaknesses in global healthcare services. The blood supply in Africa is a critical element of the healthcare service that may be significantly affected by the pandemic. By implementing principles of patient blood management, primary healthcare practitioners may play an important role in the resilience of the blood supply during the COVID-19 pandemic.


Asunto(s)
Seguridad de la Sangre , Infecciones por Coronavirus/epidemiología , Pandemias , Rol del Médico , Médicos de Atención Primaria , Neumonía Viral/epidemiología , África/epidemiología , Humanos
11.
Med. clín (Ed. impr.) ; 154(11): 425-432, jun. 2020. graf, tab
Artículo en Español | IBECS | ID: ibc-195534

RESUMEN

INTRODUCCIÓN: La transfusión isogrupo ABO D es la práctica transfusional habitual, sin embargo, cuando no se dispone de sangre D negativo puede ser preciso transfundir concentrados de hematíes D positivo a pacientes D negativo. Estos pacientes pueden desarrollar aloanticuerpos anti-D en los siguientes 3 meses a la exposición. MATERIAL Y MÉTODO: En los últimos 18 años, hemos experimentado situaciones de escasez de sangre D negativo, en las que hemos aplicado un protocolo clínico asistencial, seleccionando s los pacientes según el riesgo de aloinmunización y de requerimientos transfusionales crónicos. Se realizó una recogida prospectiva de estos pacientes, analizando principalmente la aloinmunización y la mortalidad. RESULTADOS: Tras las aplicación del protocolo se han transfundido unidades D positivo al 3% de los pacientes D negativo, con una tasa de aloinmunización conocida del 12,3%, siendo mayor en los pacientes más jóvenes y en aquellos que han recibido mayor número de unidades. No se detectaron complicaciones secundarias a la inmunización y la mortalidad en este grupo fue menor. CONCLUSIÓN: La transfusión de hematíes D positivo a pacientes D negativo no solo es una práctica segura para pacientes seleccionados, sino que además permite optimizar el uso de un producto en situaciones de escasez


BACKGROUND: To transfuse packed red blood cells isogroup ABO D is a usual transfusion practice. However, when there is not enough D negative blood available, we can transfuse positive red blood cells to negative patients. Immunocompetent D negative individuals may develop serologically detectable anti-D antibodies within 3 months after exposure to D positive red blood cells. MATERIAL AND METHOD: Over the last 18 years, we have experienced situations of D negative blood cell scarcity. In these situations, we have applied a clinical assistance protocol, selecting patients with lower risk of alloimmunization and chronic transfusion requirements. We have retrospectively evaluated this policy for the use of D positive red blood cells in D negative patients, focussing on alloinmunization and mortality. RESULTS: Applying the protocol, 3% of D negative patients were transfused with D positive units, with an alloimmunization rate of 12.3%. The rate of alloimmunization was higher in the younger age group and in those transfused with more units. No haemolytic reactions were reported. Mortality in the alloimmunized group was lower. CONCLUSION: The use of D positive red blood cells in selected D negative patients does not induce adverse reactions, is a safe practice and allows saving of a product that is sometimes limited


Asunto(s)
Humanos , Masculino , Femenino , Anciano , Anciano de 80 o más Años , Transfusión de Eritrocitos/métodos , Isoinmunización Rh , Globulina Inmune rho(D)/sangre , Histocompatibilidad , Estudios Retrospectivos , Epítopos , Seguridad de la Sangre/métodos , Análisis Multivariante , Isoanticuerpos/sangre
13.
Arch Soc Esp Oftalmol ; 95(6): 300-310, 2020 Jun.
Artículo en Inglés, Español | MEDLINE | ID: mdl-32409243

RESUMEN

OBJECTIVE: Minimize exposure to the SARS-CoV-2, reduce the chances of cross-transmission between patients and healthcare personnel, and prevent the development of postoperative complications from the management of patients with eye diseases during the 2019 coronavirus disease pandemic (COVID-19). METHODS: COVID-19 literature review and consensus establishment between different Spanish ophthalmology societies in order to provide guidelines and recommendations of maximum resources primarily conditioned by the state of alert, confinement and social distancing that occurs in Spain since March 16, 2020. RESULTS: The recommendations will promote the adoption of action and protection measures for eye care in outpatient clinics, surgical areas and hospitalization, for unconfirmed (asymptomatic and symptomatic) and confirmed COVID-19 patients. Measures must be adapted to the circumstances and availability of personal protective equipment in each of the centers and Autonomous Communities, which will be updated according to the pandemic phases and the measures adopted by the Spanish Government. CONCLUSIONS: During the COVID-19 pandemic, attention to the potential health risks to the population caused by coronavirus should prevail over the possible progression of the common eye diseases. Ophthalmologists and other eye care professionals must assume a possible progression of these diseases due to the impossibility of adequate patient follow-up.


Asunto(s)
Betacoronavirus , Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/transmisión , Oftalmopatías/diagnóstico , Transmisión de Enfermedad Infecciosa de Paciente a Profesional/prevención & control , Pandemias , Neumonía Viral/epidemiología , Neumonía Viral/transmisión , Complicaciones Posoperatorias/prevención & control , Antimaláricos/uso terapéutico , Enfermedades Asintomáticas , Seguridad de la Sangre , Cloroquina/uso terapéutico , Lentes de Contacto , Infecciones por Coronavirus/diagnóstico , Infecciones por Coronavirus/prevención & control , Progresión de la Enfermedad , Oftalmopatías/terapia , Humanos , Hidroxicloroquina/uso terapéutico , Procedimientos Quirúrgicos Oftalmológicos/efectos adversos , Procedimientos Quirúrgicos Oftalmológicos/métodos , Oftalmología , Pandemias/prevención & control , Neumonía Viral/diagnóstico , Neumonía Viral/prevención & control , Factores de Riesgo , Sociedades Médicas , España , Evaluación de Síntomas/métodos , Privación de Tratamiento
14.
Vox Sang ; 115(6): 536-542, 2020 08.
Artículo en Inglés | MEDLINE | ID: mdl-32384164
15.
Transfusion ; 60(5): 974-985, 2020 05.
Artículo en Inglés | MEDLINE | ID: mdl-32357261

RESUMEN

BACKGROUND: The high incidence of septic transfusion reactions (STRs) led to testing being mandated by AABB from 2004. This was implemented by primary culture of single-donor apheresis platelets (APs) from 2004 and prestorage pooled platelets (PSPPs) from 2007. STUDY DESIGN/METHODS: Platelet (PLT) aliquots were cultured at issue and transfusion reactions evaluated at our hospital. Bacterial contamination and STR rates (shown as rates per million transfusions in Results) were evaluated before and after introduction of primary culture by blood centers that used a microbial detection system (BacT/ALERT, bioMerieux) or enhanced bacterial detection system (eBDS, Haemonetics). RESULTS: A total of 28,457 PLTs were cultured during pre-primary culture periods (44.7% APs; 55.3% at-issue pooled PLTs [AIPPs]) and 97,595 during post-primary culture periods (79.3% APs; 20.7% PSPPs). Forty-three contaminated units were identified in preculture and 34 in postculture periods (rates, 1511 vs. 348; p < 0.0001). Contamination rates of APs were significantly lower than AIPPs in the preculture (393 vs. 2415; p < 0.0001) but not postculture period compared to PSPPs (387 vs. 198; p = 0.9). STR rates (79 vs. 90; p = 0.98) were unchanged with APs but decreased considerably with pooled PLTs (826 vs. 50; p = 0.0006). Contamination (299 vs. 324; p = 0.84) and STR rates (25 vs. 116; p = 0.22) were similar for PLTs tested by BacT/ALERT and eBDS primary culture methods. A change in donor skin preparation method in 2012 was associated with decreased contamination and STR rates. CONCLUSION: Primary culture significantly reduced bacterial contamination and STR associated with pooled but not AP PLTs. Measures such as secondary testing near time of use or pathogen reduction are needed to further reduce STRs.


Asunto(s)
Infecciones Bacterianas/epidemiología , Contaminación de Medicamentos/estadística & datos numéricos , Transfusión de Plaquetas , Cultivo Primario de Células , Sepsis/epidemiología , Reacción a la Transfusión/epidemiología , Centros Médicos Académicos , Adulto , Infecciones Bacterianas/sangre , Infecciones Bacterianas/transmisión , Eliminación de Componentes Sanguíneos/efectos adversos , Eliminación de Componentes Sanguíneos/historia , Eliminación de Componentes Sanguíneos/normas , Eliminación de Componentes Sanguíneos/estadística & datos numéricos , Plaquetas/citología , Plaquetas/microbiología , Seguridad de la Sangre/efectos adversos , Seguridad de la Sangre/historia , Seguridad de la Sangre/estadística & datos numéricos , Transfusión Sanguínea/historia , Transfusión Sanguínea/estadística & datos numéricos , Células Cultivadas , Niño , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Incidencia , Transfusión de Plaquetas/efectos adversos , Transfusión de Plaquetas/historia , Transfusión de Plaquetas/estadística & datos numéricos , Cultivo Primario de Células/historia , Cultivo Primario de Células/normas , Cultivo Primario de Células/estadística & datos numéricos , Estudios Retrospectivos , Sepsis/sangre , Sepsis/etiología , Reacción a la Transfusión/microbiología , Estados Unidos/epidemiología
16.
Transfusion ; 60(6): 1119-1122, 2020 06.
Artículo en Inglés | MEDLINE | ID: mdl-32361996

RESUMEN

Oral swabs, sputum, and blood samples from 18 asymptomatic and symptomatic patients with SARS-CoV-2 infection were examined using RT-PCR testing in order to assess the risk of transfusion-related transmission. In asymptomatic patients as well as patients with flu-like symptoms and fever, no SARS-CoV-2 RNA could be detected in the blood or serum despite a clearly positive result in all throat swabs. As patients with symptoms of infectious disease will not be admitted to blood donation, the risk for transfusion transmission of SARS-CoV-2 seems to be negligible.


Asunto(s)
Infecciones Asintomáticas , Betacoronavirus/aislamiento & purificación , Donantes de Sangre , Seguridad de la Sangre , Infecciones por Coronavirus/transmisión , Selección de Donante , Neumonía Viral/transmisión , Reacción a la Transfusión/prevención & control , Adolescente , Adulto , Anciano , Infecciones por Coronavirus/sangre , Infecciones por Coronavirus/diagnóstico , Femenino , Alemania , Humanos , Masculino , Persona de Mediana Edad , Pandemias , Neumonía Viral/sangre , Neumonía Viral/diagnóstico , Reacción a la Transfusión/virología , Adulto Joven
17.
Transfusion ; 60(8): 1778-1784, 2020 08.
Artículo en Inglés | MEDLINE | ID: mdl-32442333

RESUMEN

BACKGROUND: The aim of this study was to estimate the number of blood donors during the COVID-19 incubation period across China. STUDY DESIGN AND METHODS: In this study, we developed a predictive model to estimate the number of blood donors during the COVID-19 incubation period among 34 provincial regions in China. Our main assumption was that blood donors of all ages in different regions have a stable blood donation intention and the same infection risk. RESULTS: First, we estimated the number of blood donors during the COVID-19 incubation period in Wuhan city, Hubei Province, and China, from December 31, 2019 to March 17, 2020. Second, we compared the number of blood donors during the COVID-19 incubation period in all provinces across China. In addition, we found that if all RBCs, plasma, and cryoprecipitation were stored in isolation until the 14th day, the potential risk of SARS-CoV-2 transmission through blood transfusion was reduced by at least 65.77% after the blood donor safely passed the COVID-19 incubation period. Moreover, if the detection of SARS-CoV-2 RNA was carried out on all platelets, the potential risk would be reduced by 77.48%. CONCLUSIONS: Although the risk is low, with the rapid spread of the COVID-19 and the appearance of alarmingly high infectivity and a high fatality rate, appropriate measures should be taken by health departments to ensure the safety of clinical blood.


Asunto(s)
Donantes de Sangre/estadística & datos numéricos , Seguridad de la Sangre/métodos , Transfusión Sanguínea/normas , Infecciones por Coronavirus/transmisión , Neumonía Viral/transmisión , Betacoronavirus/genética , Betacoronavirus/aislamiento & purificación , Donantes de Sangre/provisión & distribución , Conservación de la Sangre , China , Infecciones por Coronavirus/prevención & control , Humanos , Periodo de Incubación de Enfermedades Infecciosas , Pandemias/prevención & control , Neumonía Viral/prevención & control , Cuarentena , ARN Viral/sangre
18.
Transfus Apher Sci ; 59(3): 102790, 2020 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-32345485

RESUMEN

Use of convalescent plasma transfusions could be of great value in the current pandemic of coronavirus disease (COVID-19), given the lack of specific preventative and therapeutic options. This convalescent plasma therapy is of particular interest when a vaccine or specific therapy is not yet available for emerging viruses, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19. This report summarizes existing literature around convalescent plasma as a therapeutic option for COVID-19. It also includes recommendations for establishing a convalescent plasma program, enhancement considerations for convalescent plasma, and considerations around pathogen reduction treatment of convalescent plasma. Time is of the essence to set up protocols for collection, preparation, and administration of apheresis-collected convalescent plasma in response to the current pandemic. The immediate use of convalescent plasma provides prompt availability of a promising treatment while specific vaccines and treatments are evaluated and brought to scale. Further development of improved convalescent plasma, vaccines and other therapeutics depends on quick generation of additional data on pathogenesis and immune response. Additionally, given the lack of information around the natural history of this disease, PRT should be considered to add a layer of safety to protect recipients of convalescent plasma.


Asunto(s)
Enfermedades Transmisibles Emergentes/terapia , Infecciones por Coronavirus/terapia , Pandemias , Neumonía Viral/terapia , Anticuerpos Neutralizantes/sangre , Anticuerpos Neutralizantes/uso terapéutico , Anticuerpos Antivirales/sangre , Anticuerpos Antivirales/uso terapéutico , Betacoronavirus/inmunología , Seguridad de la Sangre , Enfermedades Transmisibles Emergentes/virología , Convalecencia , Infecciones por Coronavirus/sangre , Infecciones por Coronavirus/prevención & control , Selección de Donante , Humanos , Inmunización Pasiva , Metaanálisis como Asunto , Pandemias/prevención & control , Plasmaféresis , Neumonía Viral/sangre , Neumonía Viral/prevención & control , Síndrome Respiratorio Agudo Grave/terapia , Estados Unidos , United States Food and Drug Administration , Inactivación de Virus
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA